We've made it our mission to save lives and transform the journey of sepsis patients worldwide.
Founded by a team of experienced diagnostic technologists and advised by leading sepsis experts, we are developing a breakthrough point of need test for sepsis which meets WHO requirements.
Current sepsis diagnostic tests do not integrate well in existing healthcare settings. Our low-cost TRISEP test has been developed to be accessible in any healthcare setting, in any part of the world.
The TRISEP test has been designed to confirm a sepsis diagnosis and guide initial treatment options within minutes in suspected sepsis cases. This will lead to earlier and more effective treatment and reduced antibiotic use.
It has become normal practice to administer broad-spectrum antibiotics immediately following initial clinical diagnosis of sepsis, even before blood tests and cultures confirm the presence of a bacterial infection.
However, in cases of non-bacterial sepsis, this can lead to unnecessary use of antibiotics (AMR), opportunistic hospital acquired infections and a delay to more appropriate treatment.
This has created a diagnostic need which to this day has failed to be filled by existing point of care tests. This is the diagnostic space that the TRISEP test has been developed to address.
The TRISEP test has been designed to confirm emergency treatment options following clinical assessment in suspected sepsis cases.
The TRISEP test is well suited for use in G.P Practices to rapidly rule out viruses and other types of infection.
The TRISEP test may be performed by community healthcare providers such as Pharmacists and at local healthcare clinics.
We are determined to see our technology in the hands of those who are fighting sepsis on the frontlines, who need rapid access to clinically relevant data to confirm their diagnosis. By implementing the TRISEP test, we believe we can reduce delays to treatment and, most importantly, save lives.
Septest wins the 2023 TBAT Innovation Challenge.
We're delighted to announce Septest has won the innovation challenge 2023. Septest not only secured the judges' vote but also won the Audience Winner vote.
Co-founder Kelly pitched at the packed showcase event alongside the nine other finalists, in a bid to claim the top prize.
Septest wins a cash prize along with a business support package provided by TBAT and its industry partners worth over £50,000.
Septest named as Top 10 Finalist
Septest has been named as one of ten finalists in the prestigious TBAT Innovation Challenge.
Septest completes Herts Healthcare Accelerator Programme.
Septest has completed the 2023 Herts Healthcare Accelerator. The programme is designed to support the development of healthcare, biotech, and MedTech innovations, including new potential products, services, or allied technologies.
The programme provided access to a range of Herts experts from across various fields including life sciences, technology, design, business, and law to enable the development of innovations and early-stage research and development (R&D).
During the programme Septest completed proof of principle studies for its groundbreaking TRISEP test at the University of Hertfordshire.
Septest wins pitch award at Northern Business Accelerator final.
We are thrilled to announce that Septest recently emerged victorious at the Northern Business Accelerator showcase event held in West Yorkshire.
After months of dedicated business support and mentorship, Septest, a groundbreaking startup, had the opportunity to pitch their sepsis diagnostic test "Dragons Den" style to a panel of esteemed investors and an audience of regional business leaders.
Septest's pitch not only impressed but won the hearts of the panel and the audience to claim the top prize. Panelist and representative Jeremey Meadowcroft commended Septest, stating, "Septest is an innovative and vital tool, destined for both business success and saving lives."
We are always looking to forge connections with like-minded individuals and organisations in order to get our technology closer to implementation.
We would especially welcome connections from investors and established diagnostic companies looking to venture into identification and management of sepsis treatment options.
Please contact us via the contact page for more information.